[Fax to Bruce Weniger from Alan Schultz with Attached Presentation]

" 30I 402 3684 VPRP DALS

tuti ca" v Jo: at

Ilearning how to design (and test) an HIV Vaccine!!tter antibody:
oligomeric forms of envelope subunits
boosting primed (poxvector, DNA) subjects with oliogmeric subunits
will subunits from primary HIV better induce neutralization of primary HIV?
passive transfer of antibody from macaques vaccinated with live-attenuated SIV
cyt(,kine co-administration to manipulate TH1/TH2 balance
mul: i-valency?
fE tter CTL:
effe ive priming (vectors, DNA)
include gag, pol, and nef epitopes
boo sting with protein (surprisingly) has helped in humans
cytc kine co-administration
C 'emokine::
perfbrm neutralization tests in cells with only one co-recptor
test chemokines as correlate of protection
passive administration of chemokines
blocking of CCR5 co-receptor
M1 icosal im.nune response:
loca. immune responses attempted by local vaccine administration
mea.;urement and manipulation of Thl/Th2 profiles
C,: rrelates cf Immunity:
intersive investigation of humoral, cellular, and chemokine
mechanisms of live-attenuated SV vaccine in macaques
care:i examination of exposed but uninfected human populations
bettwr analysis of neutralization, utilizing new knowledge of co-receptor involvement
P mnate Evatuation:
SHIV permits evaluation of vaccines containig HIV envelope components
pathbgenic SHIV allows test of effect on disease progression
rectsl, vaginal challenges possible with titered stocks, to model sexual transmission
plasraaviremia quantitation (for SIV or SHIV) allows comparison with HW in humans

[A.M.Schullz December 1996]